Xconomy -- Helicon Therapeutics, a San Diego biotech developing drugs to enhance memory, has raised $50 million from undisclosed investors, according to a recent filing with the U.S. Securities and Exchange Commission. Although the filing was dated June 24, it was not among the second quarter venture capital fundings in the recent MoneyTree Report, according to Emily Mendell, a spokeswoman for the National Venture Capital Association.
